19 / 26
Page 46
Notes:
allied
academies
J Pharmacol Ther Res 2017 Volume 1 Issue 2
November 02-03, 2017 Chicago, USA
4
th
International Congress on
International Conference and Exhibition on
Drug Discovery, Designing and Development
Biochemistry, Molecular Biology: R&D
&
Novel synthetic inhibitors of eosinophils with potential anti-asthmatic activity
Tarek Aboul-Fadl
Assiut University, Egypt
A
sthma is amajor public health issuewithhigh and increasing
prevalence rates and a concomitant increase in morbidity
and mortality. Asthma is estimated to affect 300 million
people, with an expected increase to 400 million worldwide
by 2025. Many factors may have contributed to the rise of
the problem of bronchial asthma. Increasing air pollution, fast
modernization, and widespread construction work are some of
the reasons for asthma to thrive. The situation is complicated
by poor access to medical services and high price of effective
drugs.Asthma is a chronic inflammatory condition, triggered by
environmental factors in genetically predisposed individuals,
and is characterized by mast cell, T lymphocyte, and eosinophil
infiltrates in the bronchial mucosa. Eosinophils are recruited
to sites of specific inflammatory reactions, especially during
allergic diseases and are correlated with asthma severity. In
spite of their numerous adverse effects inhaled glucocortocoids
have been established as the standard treatment for asthma.
Therefore, an urgent need exists for alternative treatments
to overcome these undesirable side effects of steroid therapy
and to provide another effective agent for the treatment of
asthma. Lidocaine was reported to inhibit interleukin-5 (IL-5)-
mediated survival and activation of human eosinophils. It can
replace inhaled glucocorticoids for the treatment of asthma;
however, lidocaine has many undesired side effects mainly due
to its sodium channel activity including anesthesia. Accordingly,
the current work aims to modify lidocaine structure to obtain
analogs with minimum sodium channel and enhanced IL-5
inhibitory activity. The hypothesis supported by ligand-based
pharmacophore modeling generated using different molecular
modeling programs.
Speaker Biography
Tarek Aboul-Fadl is a Prof. of Medicinal Chemistry at Faculty of Pharmacy, Assiut
University/Egypt. Dr Aboul-Fadl received his PhD in Pharmaceutical Medicinal
Chemistry from Assiut University (1994) under the channel system and joint
supervision scheme between Assiut University and Josai University/Japan. Dr Aboul-
Fadl performed his postdoctoral training as a postdoctoral research fellow and Scientist
at Institute of Pharmaceutical Chemistry, University of Vienna, Austria (1997- 1998),
Institute of Pharmacy and Food Chemistry, University of Erlangen-Nürnberg, Germany
(1999 and 2013) and Department of Medicinal Chemistry, University of Utah, USA
(2001-2002 and 2004-2005). Dr Aboul-Fadl joined Department of Medicinal Chemistry
as an assistant Prof. in 1994, then promoted to associate Prof. in 1999 and to Professor
in 2004. Dr Aboul-Fadl is a member of Egyptian Syndicate of Pharmacists since 1984,
Egyptian Society of Pharmacists since 1994, American Chemical Society since 2002 and
The Stop TB Partnership Working Group on New TB Drugs (WGND) since Feb. 2010
e:
fadl@aun.edu.eg